Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesamorelin for NAFLD and Cardiovascular Risk
NCT03375788Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2019
- Primary completion
- Jul 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing Tesamorelin with Placebo (2 arms). Primary endpoint: Liver Fat Content at 12 months. Started Jan 2019; status: completed.
02
Drugs
tesamorelin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03375788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03375788.